Loading…

Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control

The aim of this study was to establish whether glycemic control results in decrease of C-reactive protein (CRP) in Type 2 diabetic subjects. Newly diagnosed Type 2 diabetic subjects were recruited and followed-up by 6-month intensive medical management. All the participants were carefully interviewe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2003-03, Vol.26 (3), p.216-221
Main Authors: RODRIGUEZ-MORAN, M, GUERRERO-ROMERO, F
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133
cites cdi_FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133
container_end_page 221
container_issue 3
container_start_page 216
container_title Journal of endocrinological investigation
container_volume 26
creator RODRIGUEZ-MORAN, M
GUERRERO-ROMERO, F
description The aim of this study was to establish whether glycemic control results in decrease of C-reactive protein (CRP) in Type 2 diabetic subjects. Newly diagnosed Type 2 diabetic subjects were recruited and followed-up by 6-month intensive medical management. All the participants were carefully interviewed, clinically examined, and laboratory tested to exclude conditions likely to provoke an inflammatory response, which was an exclusion criterium. CRP was measured by automated microparticle enzyme immunoassay (IMx, Abbott Laboratories, USA). Two-hundred and forty-eight patients were included in the analysis of data. At baseline, average CRP levels were of 9.6 +/- 6.2 mg/l. Only 14 (5.7%) patients showed a fasting glucose equal or lower than 6.1 mmo/l (5.6 +/- 0.4 mmo/l); of them, 6 (42.8%) had elevated CRP levels (8.8 +/- 6.7 mg/l). The fasting glucose in the 234 (94.3%) non-controlled subjects was 13.1 +/- 4.8 mmol/l; of them 179 (76.5%) subjects showed elevated CRP levels (10.9 +/- 6.5 mg/I). At the end of the 6-month follow-up, the average fasting glucose and HbA1c in the overall group decreased from 12.5 +/- 5.0 to 9.0 +/- 1.6 mmol/l, p < 0.00001, and 13.0 +/- 4.9 to 8.9 +/- 2.9%, p < 0.00001, which resulted in a significant reduction of CRP levels (9.6 +/- 6.2 to 6.3 +/- 3.0 mg/l, p < 0.00001). Seventy-one (28.6%) patients reached glycemic control; however, only 29 (40.8%) of them reduced the CRP levels to 3 mg/l or less (1.3 +/- 1.9 mg/l), and the remaining 42 controlled patients maintained high CRP concentration (4.2 +/- 1.2 mg/I), p < 0.00001. Concentration of CRP is moderately influenced by glycemic control in the Type 2 diabetic subjects.
doi_str_mv 10.1007/BF03345160
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73434168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73434168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133</originalsourceid><addsrcrecordid>eNpFkNGK1TAQhoMo7nH1xgeQ3OiFUM10epr00j3sqrDgzXpdpslUs6TtMUlX-gC-t1n2wIGBYeCb_5_5hXgL6hMopT9f3SjEZg-teiZ2oGtVGTTtc7FT2EHVqE5fiFcp3SuFGo1-KS6gNqoDDTvx7zrwA2V20i6z5TlHyn6Zk1xGeagik83-geUxLpn9LEuldbhnm5P86_NvebcdWdbSeRo4c5ITh-DzmiRFltPiuOhx2MriGFYuDk4Om_wVNsuTt4-mOS7htXgxUkj85tQvxc-b67vDt-r2x9fvhy-3lUXAXA0KyVALjEDk9s5By1wbR3bkQSkDBggIqdMKymRJt9TQ3tTdADQA4qX48KRb_vmzcsr95JMtJ9PMy5p6jQ020JoCfnwCbVxSijz2x-gnilsPqn8MvT-HXuB3J9V1mNid0VPKBXh_AihZCmOk2fp05hrTNLVG_A_cMot7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73434168</pqid></control><display><type>article</type><title>Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control</title><source>Springer Nature</source><creator>RODRIGUEZ-MORAN, M ; GUERRERO-ROMERO, F</creator><creatorcontrib>RODRIGUEZ-MORAN, M ; GUERRERO-ROMERO, F</creatorcontrib><description>The aim of this study was to establish whether glycemic control results in decrease of C-reactive protein (CRP) in Type 2 diabetic subjects. Newly diagnosed Type 2 diabetic subjects were recruited and followed-up by 6-month intensive medical management. All the participants were carefully interviewed, clinically examined, and laboratory tested to exclude conditions likely to provoke an inflammatory response, which was an exclusion criterium. CRP was measured by automated microparticle enzyme immunoassay (IMx, Abbott Laboratories, USA). Two-hundred and forty-eight patients were included in the analysis of data. At baseline, average CRP levels were of 9.6 +/- 6.2 mg/l. Only 14 (5.7%) patients showed a fasting glucose equal or lower than 6.1 mmo/l (5.6 +/- 0.4 mmo/l); of them, 6 (42.8%) had elevated CRP levels (8.8 +/- 6.7 mg/l). The fasting glucose in the 234 (94.3%) non-controlled subjects was 13.1 +/- 4.8 mmol/l; of them 179 (76.5%) subjects showed elevated CRP levels (10.9 +/- 6.5 mg/I). At the end of the 6-month follow-up, the average fasting glucose and HbA1c in the overall group decreased from 12.5 +/- 5.0 to 9.0 +/- 1.6 mmol/l, p &lt; 0.00001, and 13.0 +/- 4.9 to 8.9 +/- 2.9%, p &lt; 0.00001, which resulted in a significant reduction of CRP levels (9.6 +/- 6.2 to 6.3 +/- 3.0 mg/l, p &lt; 0.00001). Seventy-one (28.6%) patients reached glycemic control; however, only 29 (40.8%) of them reduced the CRP levels to 3 mg/l or less (1.3 +/- 1.9 mg/l), and the remaining 42 controlled patients maintained high CRP concentration (4.2 +/- 1.2 mg/I), p &lt; 0.00001. Concentration of CRP is moderately influenced by glycemic control in the Type 2 diabetic subjects.</description><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/BF03345160</identifier><identifier>PMID: 12809171</identifier><identifier>CODEN: JEIND7</identifier><language>eng</language><publisher>Milano: Kurtis</publisher><subject>Adult ; Aged ; Associated diseases and complications ; Biological and medical sciences ; Blood Glucose - metabolism ; C-Reactive Protein - metabolism ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Drug Therapy, Combination ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fasting - blood ; Female ; Glyburide - therapeutic use ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Lipids - blood ; Male ; Medical sciences ; Metformin - therapeutic use ; Middle Aged ; Osmolar Concentration</subject><ispartof>Journal of endocrinological investigation, 2003-03, Vol.26 (3), p.216-221</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133</citedby><cites>FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14844273$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12809171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RODRIGUEZ-MORAN, M</creatorcontrib><creatorcontrib>GUERRERO-ROMERO, F</creatorcontrib><title>Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><description>The aim of this study was to establish whether glycemic control results in decrease of C-reactive protein (CRP) in Type 2 diabetic subjects. Newly diagnosed Type 2 diabetic subjects were recruited and followed-up by 6-month intensive medical management. All the participants were carefully interviewed, clinically examined, and laboratory tested to exclude conditions likely to provoke an inflammatory response, which was an exclusion criterium. CRP was measured by automated microparticle enzyme immunoassay (IMx, Abbott Laboratories, USA). Two-hundred and forty-eight patients were included in the analysis of data. At baseline, average CRP levels were of 9.6 +/- 6.2 mg/l. Only 14 (5.7%) patients showed a fasting glucose equal or lower than 6.1 mmo/l (5.6 +/- 0.4 mmo/l); of them, 6 (42.8%) had elevated CRP levels (8.8 +/- 6.7 mg/l). The fasting glucose in the 234 (94.3%) non-controlled subjects was 13.1 +/- 4.8 mmol/l; of them 179 (76.5%) subjects showed elevated CRP levels (10.9 +/- 6.5 mg/I). At the end of the 6-month follow-up, the average fasting glucose and HbA1c in the overall group decreased from 12.5 +/- 5.0 to 9.0 +/- 1.6 mmol/l, p &lt; 0.00001, and 13.0 +/- 4.9 to 8.9 +/- 2.9%, p &lt; 0.00001, which resulted in a significant reduction of CRP levels (9.6 +/- 6.2 to 6.3 +/- 3.0 mg/l, p &lt; 0.00001). Seventy-one (28.6%) patients reached glycemic control; however, only 29 (40.8%) of them reduced the CRP levels to 3 mg/l or less (1.3 +/- 1.9 mg/l), and the remaining 42 controlled patients maintained high CRP concentration (4.2 +/- 1.2 mg/I), p &lt; 0.00001. Concentration of CRP is moderately influenced by glycemic control in the Type 2 diabetic subjects.</description><subject>Adult</subject><subject>Aged</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>C-Reactive Protein - metabolism</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Drug Therapy, Combination</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fasting - blood</subject><subject>Female</subject><subject>Glyburide - therapeutic use</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Osmolar Concentration</subject><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkNGK1TAQhoMo7nH1xgeQ3OiFUM10epr00j3sqrDgzXpdpslUs6TtMUlX-gC-t1n2wIGBYeCb_5_5hXgL6hMopT9f3SjEZg-teiZ2oGtVGTTtc7FT2EHVqE5fiFcp3SuFGo1-KS6gNqoDDTvx7zrwA2V20i6z5TlHyn6Zk1xGeagik83-geUxLpn9LEuldbhnm5P86_NvebcdWdbSeRo4c5ITh-DzmiRFltPiuOhx2MriGFYuDk4Om_wVNsuTt4-mOS7htXgxUkj85tQvxc-b67vDt-r2x9fvhy-3lUXAXA0KyVALjEDk9s5By1wbR3bkQSkDBggIqdMKymRJt9TQ3tTdADQA4qX48KRb_vmzcsr95JMtJ9PMy5p6jQ020JoCfnwCbVxSijz2x-gnilsPqn8MvT-HXuB3J9V1mNid0VPKBXh_AihZCmOk2fp05hrTNLVG_A_cMot7</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>RODRIGUEZ-MORAN, M</creator><creator>GUERRERO-ROMERO, F</creator><general>Kurtis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control</title><author>RODRIGUEZ-MORAN, M ; GUERRERO-ROMERO, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>C-Reactive Protein - metabolism</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Drug Therapy, Combination</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fasting - blood</topic><topic>Female</topic><topic>Glyburide - therapeutic use</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Osmolar Concentration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RODRIGUEZ-MORAN, M</creatorcontrib><creatorcontrib>GUERRERO-ROMERO, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RODRIGUEZ-MORAN, M</au><au>GUERRERO-ROMERO, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control</atitle><jtitle>Journal of endocrinological investigation</jtitle><addtitle>J Endocrinol Invest</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>26</volume><issue>3</issue><spage>216</spage><epage>221</epage><pages>216-221</pages><issn>0391-4097</issn><eissn>1720-8386</eissn><coden>JEIND7</coden><abstract>The aim of this study was to establish whether glycemic control results in decrease of C-reactive protein (CRP) in Type 2 diabetic subjects. Newly diagnosed Type 2 diabetic subjects were recruited and followed-up by 6-month intensive medical management. All the participants were carefully interviewed, clinically examined, and laboratory tested to exclude conditions likely to provoke an inflammatory response, which was an exclusion criterium. CRP was measured by automated microparticle enzyme immunoassay (IMx, Abbott Laboratories, USA). Two-hundred and forty-eight patients were included in the analysis of data. At baseline, average CRP levels were of 9.6 +/- 6.2 mg/l. Only 14 (5.7%) patients showed a fasting glucose equal or lower than 6.1 mmo/l (5.6 +/- 0.4 mmo/l); of them, 6 (42.8%) had elevated CRP levels (8.8 +/- 6.7 mg/l). The fasting glucose in the 234 (94.3%) non-controlled subjects was 13.1 +/- 4.8 mmol/l; of them 179 (76.5%) subjects showed elevated CRP levels (10.9 +/- 6.5 mg/I). At the end of the 6-month follow-up, the average fasting glucose and HbA1c in the overall group decreased from 12.5 +/- 5.0 to 9.0 +/- 1.6 mmol/l, p &lt; 0.00001, and 13.0 +/- 4.9 to 8.9 +/- 2.9%, p &lt; 0.00001, which resulted in a significant reduction of CRP levels (9.6 +/- 6.2 to 6.3 +/- 3.0 mg/l, p &lt; 0.00001). Seventy-one (28.6%) patients reached glycemic control; however, only 29 (40.8%) of them reduced the CRP levels to 3 mg/l or less (1.3 +/- 1.9 mg/l), and the remaining 42 controlled patients maintained high CRP concentration (4.2 +/- 1.2 mg/I), p &lt; 0.00001. Concentration of CRP is moderately influenced by glycemic control in the Type 2 diabetic subjects.</abstract><cop>Milano</cop><pub>Kurtis</pub><pmid>12809171</pmid><doi>10.1007/BF03345160</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0391-4097
ispartof Journal of endocrinological investigation, 2003-03, Vol.26 (3), p.216-221
issn 0391-4097
1720-8386
language eng
recordid cdi_proquest_miscellaneous_73434168
source Springer Nature
subjects Adult
Aged
Associated diseases and complications
Biological and medical sciences
Blood Glucose - metabolism
C-Reactive Protein - metabolism
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Drug Therapy, Combination
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Fasting - blood
Female
Glyburide - therapeutic use
Humans
Hypoglycemic Agents - therapeutic use
Insulin - therapeutic use
Lipids - blood
Male
Medical sciences
Metformin - therapeutic use
Middle Aged
Osmolar Concentration
title Elevated concentrations of C-reactive protein in subjects with Type 2 diabetes mellitus are moderately influenced by glycemic control
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A13%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20concentrations%20of%20C-reactive%20protein%20in%20subjects%20with%20Type%202%20diabetes%20mellitus%20are%20moderately%20influenced%20by%20glycemic%20control&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=RODRIGUEZ-MORAN,%20M&rft.date=2003-03-01&rft.volume=26&rft.issue=3&rft.spage=216&rft.epage=221&rft.pages=216-221&rft.issn=0391-4097&rft.eissn=1720-8386&rft.coden=JEIND7&rft_id=info:doi/10.1007/BF03345160&rft_dat=%3Cproquest_cross%3E73434168%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c313t-b03a8a61e31aad5dd16ee28dacfeb008181a1a3a9701081ca76a4a5829b1ab133%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73434168&rft_id=info:pmid/12809171&rfr_iscdi=true